I-Mab Announces Upcoming Participation at January Conferences

Rhea-AI Summary

I-Mab (Nasdaq: IMAB), a clinical stage biopharmaceutical company, announced its participation in several upcoming conferences in January 2021. Key events include the H.C. Wainwright BioConnect 2021 Conference on January 11, and the Citi and UBS Greater China Healthcare Corporate Days on January 14-15 and January 18-22, respectively. Notable management participants include founder Dr. Jingwu Zang and CEO Dr. Joan Huaqiong Shen. I-Mab focuses on developing novel biologics for immuno-oncology and autoimmune diseases, striving to transition into a fully integrated global biopharmaceutical entity.

Positive

• Participation in significant industry conferences may enhance visibility and investor relations.
• Company has a robust pipeline of over 10 clinical and pre-clinical drug candidates.
• Transitioning towards a fully integrated global biopharmaceutical company indicates strong growth potential.

Negative

• None.

SHANGHAI and GAITHERSBURG, Md., Dec. 23, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in January. Details of the conferences and management presentation are as follows:

H.C. Wainwright BioConnect 2021 Conference (Virtual)
Presentation: Monday, January 11, 2021 at 6:00 a.m. EST
Presenters: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR Director

Webcast link: https://journey.ct.events/view/55113ae1-5386-4315-9899-fa6c5550c2b9. The webcast will also be available under "Event Calendar" on IMAB's IR website at http://ir.i-mabbiopharma.com/.

For more information, please contact your H.C. Wainwright representative.

Citi Greater China Healthcare Corporate Day 2021 (Virtual)
Management participants: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR Director

One-on-one and small group meetings: January 14-15, 2021

For more information, please contact your Citi representative.

UBS Greater China Conference 2021 (Virtual)
Management participants: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR Director

One-on-one and small group meetings: January 18-22, 2021

For more information, please contact your UBS representative.

About I-Mab

I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development and soon commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company's Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnerships. The Company is on track to transitioning from a clinical stage biotech company toward a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, world-class GMP manufacturing facility and commercial capability. I-Mab has offices in Beijing, Shanghai, Hangzhou, Hong Kong and Maryland, United States. For more information, please visit http://ir.i-mabbiopharma.com and follow I-Mab on LinkedIn, Twitter and WeChat.

For more information, please contact:

I-Mab

Jielun Zhu, Chief Financial Officer
E-mail: jielun.zhu@i-mabbiopharma.com
Office line: +86 21 6057 8000

Gigi Feng, Chief Communications Officer
E-mail: gigi.feng@i-mabbiopharma.com
Office line: +86 21 6057 5785

Investor Inquiries:

The Piacente Group, Inc.
Emilie Wu
E-mail: emilie@thepiacentegroup.com
Office line: + 86 21 6039 8363

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/i-mab-announces-upcoming-participation-at-january-conferences-301198031.html

SOURCE I-Mab

FAQ

What is I-Mab's participation in January conferences 2021?

I-Mab will participate in the H.C. Wainwright BioConnect 2021 Conference on January 11, followed by the Citi Greater China Healthcare Corporate Day on January 14-15, and the UBS Greater China Conference from January 18-22.

Who are the key management participants from I-Mab at these conferences?

Key participants include founder Dr. Jingwu Zang, CEO Dr. Joan Huaqiong Shen, CFO Mr. Jielun Zhu, and Senior IR Director Ms. Leah Liu.

What is I-Mab's focus as a company?

I-Mab focuses on the discovery, development, and commercialization of novel biologics for immuno-oncology and autoimmune diseases.

What is the significance of I-Mab's conference participation for investors?

Participation in these conferences enhances I-Mab's visibility and could provide valuable insights into its growth strategies and pipeline developments.